LivaNova (LIVN) Insider Todd Schermerhorn Sells $39K of Stock

LivaNova PLC (NASDAQ: LIVN) experienced notable insider activity on June 15, 2026, as Todd Schermerhorn sold 486 shares of the medical device manufacturer. According to the Form 4 filing with the Securities and Exchange Commission, the transaction was executed at an average price of $79.70 per share, totaling $38,734.20.

Insider Buying and Selling at LivaNova PLC

The transaction slightly reduced Schermerhorn's equity in the company. He received $79.70 per share for the 486 shares. This transaction was not executed under a pre-planned Rule 10b5-1 trading arrangement, which executives often use to schedule automatic stock trades in advance.

LivaNova Stock Performance and Key Technicals

On Wednesday, LivaNova shares were priced at $79.48. The company's stock has shown solid momentum, maintaining a position above its 200-day moving average of $70.76 and hovering close to its 50-day moving average of $79.86. Over the last year, the stock has traded in a wide range, between $48.82 and $85.76. LivaNova currently carries a market capitalization of $4.29 billion.

Recent Earnings

LivaNova has demonstrated steady financial results, generating $1.47 billion in revenue. The company posted a revenue growth rate of 10.8%, accompanied by a net margin of 12.81% and a return on equity of 15.4%. The stock is valued at a price-to-earnings ratio of 23.06, while its forward price-to-earnings ratio is 16.71. The company's next earnings report is scheduled for November 4, 2026.

Broader Insider Activity at LivaNova

Schermerhorn’s transaction was part of a larger wave of insider activity at the company on June 15, 2026. Chief Innovation Officer Ahmet Tezel acquired 2,965 shares, and four other insiders—Enxing Seng Stacy, Francesco Bianchi, Donald Zurbay, and Barry James Christopher—each purchased 2,383 shares. On the selling side, Peter Wilver disposed of 4,042 shares on the exact same day. These simultaneous moves showcase a mix of sentiment among the medical technology firm's leadership team.

Wall Street Analyst Sentiment on LivaNova

Wall Street analysts generally view LivaNova in a positive light, with ten analyst opinions yielding a consensus buy recommendation. On October 7, 2026, Barclays initiated coverage on the stock with an Overweight rating and set a price target of $105.00. Piper Sandler reiterated its Overweight rating on September 2, 2026, raising its price target to $90.00. Earlier, on August 5, 2026, Needham kept a Buy rating with a target of $93.00, and Mizuho maintained an Outperform rating with a $95.00 target on July 15, 2026. Freedom Capital Markets initiated coverage on July 1, 2026, with a Hold rating and an $81.00 target, while Keybanc kept an Overweight rating on June 22, 2026, with a $92.00 price target. The average price target among analysts sits at $89.10.

About LivaNova

LivaNova PLC is a medical technology company based in Gloucester, United Kingdom. The company designs and manufactures cardiopulmonary and neuromodulation equipment. Its cardiopulmonary business produces heart-lung machines and autotransfusion systems, while its neuromodulation division builds therapies and implantable devices to treat drug-resistant epilepsy and depression.

What's Next for LivaNova

Investors will likely keep a close eye on LivaNova's upcoming quarterly financial release on November 4, 2026, to assess whether the company can maintain its double-digit revenue growth. While insider sales can happen for many personal reasons, tracking whether executive buying or selling dominates future filings will help clarify how the leadership team views LivaNova's valuation.